Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners extends collaboration with Versartis

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Clinical study results show no increased risk of CV events associated with SYMLIN injection

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications